Why weight loss stalls on tirzepatide

A weight loss plateau after several months on tirzepatide is not a sign the drug has stopped working. It is the shape the curve takes. Obesity interventions of every kind tend to produce early loss, then a plateau, then progressive regain^[1], and the tirzepatide trials follow that pattern closely. The harder question, and the one people actually ask, is whether the answer to a stall is to add retatrutide. It is not, and the reason has nothing to do with opinion.

The plateau is in the trial data

SURMOUNT-1 randomised 2,539 adults with obesity and without diabetes to weekly tirzepatide or placebo for 72 weeks. Mean body weight fell 20.9% on the 15 mg dose and 3.1% on placebo^[2]. That headline number gets read as a straight line downward. It is not one. Twenty of those 72 weeks were dose escalation, and the bulk of the loss lands well before the trial ends.

SURMOUNT-4 makes the point more sharply. Its open-label lead-in ran 36 weeks at the maximum tolerated dose of 10 or 15 mg, and participants finished that phase with a mean reduction of 20.9%^[3]. Two different trials in two different populations, so this is not a like-for-like comparison. But the same figure turning up at 36 weeks in one and at 72 weeks in the other says something useful about where the loss actually happens. Three flat months somewhere after the first year is the middle of the published curve, not a departure from it.

A flat scale on treatment is not the same as no effect

SURMOUNT-4 was designed to test exactly this. At week 36 the 670 participants who completed the lead-in were randomised to stay on tirzepatide or switch to placebo for another 52 weeks. The continued group lost a further 5.5%. The placebo group regained 14.0%^[3]. By week 88, 89.5% of those still on the drug had held on to at least 80% of their lead-in loss, against 16.6% of those who stopped^[3].

Two separate findings sit in that result. Continuing still moves the number, slowly, long after the fast phase ends. And the alternative to a plateau is not a flat line, it is regain. A scale that has not shifted in three months while treatment continues is doing more work than it appears to be doing.

There is also no higher rung on this particular ladder. The US prescribing information sets the maximum adult dose at 15 mg subcutaneously once weekly^[4]. Anyone at 15 mg is already at the ceiling of what the licence covers, which is part of why the question turns outward to other molecules.

Where retatrutide actually stands

Retatrutide is an investigational triple agonist that acts at the GLP-1, GIP and glucagon receptors. It is not a stronger tirzepatide sitting on a pharmacy shelf waiting for a prescription. TRIUMPH-1, its Phase 3 obesity trial, enrolled 2,335 participants and reached primary completion on 6 April 2026^[5]. The Phase 3 evidence has only just arrived. There is no marketing authorisation for retatrutide in the United States, the European Union or the United Kingdom, and no licensed product for a prescriber to write.

The EMA is explicit about what that means for access. Medicines that are not yet authorised "are first made available through clinical trials and patients should always be considered for inclusion in trials before being offered compassionate use programmes", and compassionate use itself is reserved for "life-threatening, long-lasting or seriously debilitating illnesses, which cannot be treated satisfactorily with any currently authorised medicine"^[6]. Someone who has lost 40 lb on a licensed medicine and is holding it does not fit that description. The lawful route to retatrutide today is a trial.

Nobody has studied the two together

This is the part worth being blunt about. One registered Phase 3 protocol contains both molecules, TRIUMPH-5, and it randomises participants to receive retatrutide or tirzepatide, not both^[7]. It is a comparison, not a combination. No registered trial has tested the two given together, which means there is no efficacy data, no safety data, no interaction data and no dosing data for that pairing anywhere.

The pharmacology hints at why. Both molecules act at GLP-1 and GIP receptors, so their adverse event profiles overlap rather than complement each other. Gastrointestinal events dominate both trial programmes, and retatrutide's Phase 2 work also reported dose-dependent heart rate increases. Adding a second agonist on top of one already at full dose is not a question a forum thread can settle, and we are not going to describe how it would be attempted. The honest answer is that nobody has measured what it does.

The conversation to have instead

The useful move is a prescriber appointment framed around the plateau itself rather than around a compound you cannot lawfully obtain. Worth raising: whether the goal has quietly shifted from loss to maintenance, given what SURMOUNT-4 shows about stopping^[3]; whether anything measurable changed alongside the stall, such as sleep, alcohol or a new medicine; and which licensed options exist where you live. The country pages for the United States and the United Kingdom set out the local position, and the tirzepatide regulatory status and semaglutide pages cover what is authorised and where.

What we don't yet know

Whether adding a third receptor arm helps someone already at the top licensed dose of a dual agonist has not been tested in anybody. Whether retatrutide's Phase 2 weight loss figures hold across the full Phase 3 programme is still being published^[5]. And how long the plateau phase runs on tirzepatide before anything else changes is poorly characterised, because most trials stop before the question gets interesting.

This article is educational and is not medical advice. Decisions about a plateau, a dose, or an investigational compound belong with a clinician who knows your history. For the jurisdiction by jurisdiction picture, see retatrutide's regulatory status and the tirzepatide page.